Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Hypertonic solution effective in reducing inflammation

Research carried out at The University of Manchester has found further evidence that a simple solution, which is already used in IV drips, is an effective treatment for reducing inflammation.

From The University of Manchester 21 Sep 2012

Amgen receives FDA approval for Prolia to treat bone loss in men with osteoporosis

Amgen today announced the U.S. Food and Drug Administration (FDA) approved a new indication for Prolia (denosumab) as a treatment to increase bone mass in men with osteoporosis at high risk for fracture.

21 Sep 2012

Positive data from Nektar’s NKTR-192 Phase 1a study on acute pain

Nektar Therapeutics announced today that positive data from the first single-ascending dose Phase 1a clinical study of NKTR-192, the company's novel short-acting mu-opioid analgesic candidate, demonstrate that the drug candidate achieved its target pharmacokinetic profile.

19 Sep 2012

Friendly bacteria: do we really need to eat probiotic yogurts?

According to the World Health Organization (WHO) probiotics are “live microorganisms which when administered in adequate amounts confer a health benefit on the host”.

19 Sep 2012

Pfizer announces that 14 abstracts for tofacitinib to be presented at ACR/ARHP annual meeting

Pfizer Inc. announced today that 14 abstracts for tofacitinib, an investigational oral Janus kinase (JAK) inhibitor for the treatment of adults with moderate-to-severe active rheumatoid arthritis (RA), will be presented at the American College of Rheumatology (ACR) / Association of Rheumatology Health Professionals (ARHP) 2012 Annual Meeting, which is being held November 9-14 in Washington, D.C.

18 Sep 2012

Orthopedists should suspect necrotizing fasciitis in patients with out of proportion pain

Dr. Russell Russo, an Orthopedic Surgeon at LSU Health Sciences Center New Orleans, and other researchers stress that orthopedists should have a high index of suspicion for necrotizing fasciitis, or flesh-eating bacterial infection, in every patient with pain or other symptoms that are out of proportion to the initial diagnosis. Their recommendations are published in the September 2012 issue of Orthopedics Today.

17 Sep 2012

Scientists solve co-crystal structure of human antibody that can neutralize influenza viruses

Scientists from The Scripps Research Institute and Sea Lane Biotechnologies have solved the co-crystal structure of a human antibody that can neutralize influenza viruses in a unique way.

17 Sep 2012

Genzyme receives FDA approval for AUBAGIO to treat relapsing forms of MS

Genzyme, a Sanofi company, announced today that the U.S. Food and Drug Administration (FDA) has approved AUBAGIO (teriflunomide) as a new once-daily, oral treatment indicated for patients with relapsing forms of multiple sclerosis (MS).

13 Sep 2012

Combining two drugs may offer new and potent punch against cancer and other diseases

A new study by researchers at Weill Cornell Medical College shows combining two already-FDA approved drugs may offer a new and potent punch against diseases in which blood vessel growth is abnormal -- such as cancer, diabetic retinopathy, macular degeneration and rheumatoid arthritis.

11 Sep 2012

Plasma biomarker predicts rheumatoid arthritis onset

Healthy individuals with high levels of immunoglobulin G rheumatoid factor have a significantly increased risk for developing rheumatoid arthritis, suggests population-based research published in the BMJ.

10 Sep 2012

'No malignancy risk' with biologic response modifiers

Rheumatoid arthritis patients treated with biologic response modifiers for at least 6 months do not have a greater risk for malignancy than those given other disease-modifying drugs or placebo, conclude US and Spanish researchers.

10 Sep 2012

Top line results from Zalicus Synavive Phase 2b study in rheumatoid arthritis

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced top line results from its randomized, double-blind, placebo-controlled, Phase 2b clinical trial of Synavive in rheumatoid arthritis.

10 Sep 2012

CPF to kick off 'Pulmonary Fibrosis Awareness Month'

Each year around the world, as many as 48,000 people are diagnosed with pulmonary fibrosis and 40,000 people die – the same number of people who are lost to breast cancer annually. Pulmonary fibrosis is a devastating disease that robs people of their ability to breathe. To help raise awareness about this unknown deadly disease, the Coalition for Pulmonary Fibrosis (CPF) is kicking off "Pulmonary Fibrosis Awareness Month" this September.

10 Sep 2012

Hebrew University researcher develops anti-inflammatory and anti-allergic family of drugs

A synthetic, anti-inflammatory and anti-allergic family of drugs to combat a variety of illnesses while avoiding detrimental side effects has been developed by a Hebrew University of Jerusalem researcher.

7 Sep 2012

Absence of Puma and Bim protein leads to autoimmune diseases

Researchers at the Walter and Eliza Hall Institute have discovered that a pair of molecules work together to kill so-called 'self-reactive' immune cells that are programmed to attack the body's own organs.

7 Sep 2012

Inflammatory hindfoot arthrodesis outcomes compared

Choice of arthrodesis for patients with rheumatoid arthritis or spondyloarthritis hindfoot disease should be guided by the extent of damage present, research indicates.

6 Sep 2012

Biologic therapies do not increase risk of cancer in patients with rheumatoid arthritis

Biologic therapies developed in the last decade for rheumatoid arthritis are not associated with an increased risk of cancer when compared with traditional treatments for the condition, according to new research from The University of Texas MD Anderson Cancer Center.

6 Sep 2012

Rigel commences R343 and R333 Phase 2 studies in allergic asthma, discoid lupus erythematosus

Rigel Pharmaceuticals, Inc. today announced that it has commenced Phase 2 clinical studies with two of the company's most advanced proprietary therapeutic product candidates. R343 is an inhaled SYK inhibitor that is being evaluated as a potential treatment for allergic asthma.

6 Sep 2012

GE Healthcare introduces KUBio factory

GE Healthcare, the healthcare business of GE, today introduced KUBio, an innovative off-the-shelf, modular factory designed to save manufacturers of biopharmaceuticals both time and money.

4 Sep 2012

Infliximab may offer new hope for people with difficult-to-treat depression

Researchers at Emory University have found that a medication that inhibits inflammation may offer new hope for people with difficult-to-treat depression. The study was published Sept. 3 in the online version of Archives of General Psychiatry.

4 Sep 2012

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Hypertonic solution effective in reducing inflammation

Amgen receives FDA approval for Prolia to treat bone loss in men with osteoporosis

Positive data from Nektar’s NKTR-192 Phase 1a study on acute pain

Friendly bacteria: do we really need to eat probiotic yogurts?

Pfizer announces that 14 abstracts for tofacitinib to be presented at ACR/ARHP annual meeting

Orthopedists should suspect necrotizing fasciitis in patients with out of proportion pain

Scientists solve co-crystal structure of human antibody that can neutralize influenza viruses

Genzyme receives FDA approval for AUBAGIO to treat relapsing forms of MS

Combining two drugs may offer new and potent punch against cancer and other diseases

Plasma biomarker predicts rheumatoid arthritis onset

'No malignancy risk' with biologic response modifiers

Top line results from Zalicus Synavive Phase 2b study in rheumatoid arthritis

CPF to kick off 'Pulmonary Fibrosis Awareness Month'

Hebrew University researcher develops anti-inflammatory and anti-allergic family of drugs

Absence of Puma and Bim protein leads to autoimmune diseases

Inflammatory hindfoot arthrodesis outcomes compared

Biologic therapies do not increase risk of cancer in patients with rheumatoid arthritis

Rigel commences R343 and R333 Phase 2 studies in allergic asthma, discoid lupus erythematosus

GE Healthcare introduces KUBio factory

Infliximab may offer new hope for people with difficult-to-treat depression

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

AI in Healthcare: How generative tools are transforming clinical practice

The future of automation: Machine learning–driven hepatocyte and organoid counting

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Newsletters you may be interested in